2 results
Approved WMOCompleted
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…
Approved WMORecruiting
The primary objective of the study is to quantitatively determine the PK (distribution, metabolism, and excretion) of 14C-vosaroxin and its metabolites in patients with advanced solid tumors.The secondary objective is to evaluate safety and…